OBJECTIVE: Studies have shown an increase in the use of antipsychotics to preschoolers for disruptive behavior and aggression. This study investigated the use of atypical antipsychotics in children ≤6 years of age in Kentucky who were on Medicaid. METHODS: Kentucky Medicaid prescription claims data between 2001 and 2010 were examined for all children ≤6 years of age who had received an atypical antipsychotic. Drug type, diagnosis codes, and geographic trends were analyzed using descriptive statistics. RESULTS: A total of 70,777 prescriptions were written to 6915 distinct children ≤6 years of age. The use of atypical antipsychotics in this age group increased over the years 2001-2010 with a peak ∼ 1.0% in 2004, and averaged 0.75% in 2010. Older male children were more likely to receive atypical antipsychotics, and risperidone accounted for two thirds of the prescriptions written. Mood disorders, primarily bipolar disorder, accounted for almost 75% of the diagnoses provided. Only 32% of the prescriptions were written by child psychiatrists. Geographic analysis showed significantly higher use in the Western part of the state (more than three times the state mean in some counties). CONCLUSIONS: The use of atypical antipsychotics in children ≤6 years of age has declined from its peak, but remains substantial. The prescription rates for atypical antipsychotics by providers other than child psychiatrists, and the marked geographic variation in use across the state of Kentucky suggest that improved systems of mental healthcare for this population are needed.
OBJECTIVE: Studies have shown an increase in the use of antipsychotics to preschoolers for disruptive behavior and aggression. This study investigated the use of atypical antipsychotics in children ≤6 years of age in Kentucky who were on Medicaid. METHODS: Kentucky Medicaid prescription claims data between 2001 and 2010 were examined for all children ≤6 years of age who had received an atypical antipsychotic. Drug type, diagnosis codes, and geographic trends were analyzed using descriptive statistics. RESULTS: A total of 70,777 prescriptions were written to 6915 distinct children ≤6 years of age. The use of atypical antipsychotics in this age group increased over the years 2001-2010 with a peak ∼ 1.0% in 2004, and averaged 0.75% in 2010. Older male children were more likely to receive atypical antipsychotics, and risperidone accounted for two thirds of the prescriptions written. Mood disorders, primarily bipolar disorder, accounted for almost 75% of the diagnoses provided. Only 32% of the prescriptions were written by child psychiatrists. Geographic analysis showed significantly higher use in the Western part of the state (more than three times the state mean in some counties). CONCLUSIONS: The use of atypical antipsychotics in children ≤6 years of age has declined from its peak, but remains substantial. The prescription rates for atypical antipsychotics by providers other than child psychiatrists, and the marked geographic variation in use across the state of Kentucky suggest that improved systems of mental healthcare for this population are needed.
Authors: Nancy Scotto Rosato; Christoph U Correll; Elizabeth Pappadopulos; Alanna Chait; Stephen Crystal; Peter S Jensen Journal: Pediatrics Date: 2012-05-28 Impact factor: 7.124
Authors: Mary Margaret Gleason; Helen Link Egger; Graham J Emslie; Laurence L Greenhill; Robert A Kowatch; Alicia F Lieberman; Joan L Luby; Judith Owens; Lawrence D Scahill; Michael S Scheeringa; Brian Stafford; Brian Wise; Charles H Zeanah Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-12 Impact factor: 8.829
Authors: Julie M Zito; Daniel J Safer; Satish Valluri; James F Gardner; James J Korelitz; Donald R Mattison Journal: J Child Adolesc Psychopharmacol Date: 2007-04 Impact factor: 2.576
Authors: Haiden A Huskamp; Marcela Horvitz-Lennon; Ernst R Berndt; Sharon-Lise T Normand; Julie M Donohue Journal: Psychiatr Serv Date: 2016-07-15 Impact factor: 3.084
Authors: Deborah Winders Davis; W David Lohr; Yana Feygin; Liza Creel; Kahir Jawad; V Faye Jones; P Gail Williams; Jennifer Le; Marie Trace; Natalie Pasquenza Journal: BMC Psychiatry Date: 2021-06-10 Impact factor: 3.630
Authors: Laura J Chavez; Kelly J Kelleher; Arne Beck; Gregory N Clarke; Robert B Penfold Journal: J Child Adolesc Psychopharmacol Date: 2021-06 Impact factor: 3.031